Olshan Clients Ronin Trading and SW Investment Management Reach Agreement to Reconstitute Board of Peregrine Pharmaceuticals

Firm News

Reuters, StreetInsider and other media sources reported on the agreement reached by Olshan clients Ronin Trading and SW Investment Management with Peregrine Pharmaceuticals, Inc. pursuant to which Peregrine’s Board of Directors was reconstituted.  Pursuant to the agreement, all four of Peregrine’s long-standing incumbent directors resigned and were replaced with four new independent directors, including three designated by Ronin Trading/SW Investment Management.  Following the agreement, Peregrine has a seven-member Board consisting of entirely new directors from when Ronin Trading and SW Investment Management launched their campaign for change in July 2017.  Ryan Nebel represents Ronin Trading and SW Investment Management in connection with their investment in Peregrine Pharmaceuticals.

Media Contact

Marketing Contact
Mizi Mehaj
Marketing & Administrative Manager

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.